Patient case: 70-year-old female with breast cancer; genetic feature: AURKA amplification

Clinical trial: Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer

Summary: This pilot clinical trial studies vorinostat before surgery in treating patients with triple-negative breast cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving enzyme inhibitor therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed

Detailed description: PRIMARY OBJECTIVES:
  I. To evaluate the ability of histone deacetylase (HDAC) inhibition using suberoylanilide hydroxamic acid (SAHA) (vorinostat) to induce expression of the estrogen receptor (ER) and progesterone receptor (PR) genes in solid human triple negative invasive breast cancer.
  OUTLINE:
  Patients receive vorinostat 400 mg daily orally (PO) on days 1-21 followed by surgery within 14 days.

Eligibility: Inclusion Criteria:
  -  Resectable tumor measuring 2cm or more
  -  Histologically documented, newly diagnosed, triple negative invasive breast cancer characterized by 0% immunohistochemistry (IHC) nuclear staining for ER-alpha, 0% IHC nuclear staining for PR-alpha, and no amplification of human epidermal growth factor receptor 2 (HER2)/neu by fluorescent in situ hybridization (FISH) using institutional standard; standard IHC assays for ER and PR use antibodies to ER-alpha and PR-alpha and PR-beta
  -  Southwest Oncology Group (SWOG) performance status of less than or equal to 1
  -  Absolute neutrophil count (ANC) >= 1500/uL
  -  Hemoglobin (Hgb) >= 9 g/dL
  -  Platelets >= 100,000/uL
  -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvate transaminase (SGPT) =< 2.5 x upper limit of normal (ULN) or =< 5.0 x ULN in patients with liver metastases
  -  Creatinine =< 2.0 mg/dL or calculated creatinine clearance >= 50 ml/min
  -  Albumin >= 3 g/dL
  -  Potassium >= lower limit normal (LLN)
  -  Phosphorous >= LLN
  -  Calcium >= LLN
  -  Magnesium > LLN
  -  Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment
  -  Accessible for treatment and follow-up
  -  Written informed consent prior to study entry
  Exclusion Criteria:
  -  HER2/neu amplification by FISH
  -  Concurrent neoadjuvant anti-cancer treatment with chemotherapy, endocrine therapy, biologically targeted therapy or radiotherapy
  -  Known hypersensitivity to SAHA
  -  Preexisting hepatic impairment or renal impairment
  -  Intent to receive additional neoadjuvant therapy prior to surgery
  -  Concurrent use of an HDAC inhibitor or hydralazine
  -  Known diagnosis of human immunodeficiency virus (HIV) infection
  -  Major surgery < 4 weeks prior to starting study drug
  -  Pregnant or breastfeeding or female of reproductive potential not using an effective method of birth control
  -  Other concurrent severe, uncontrolled infection or intercurrent illness, including but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements
  -  Prior antiestrogens (selective estrogen receptor modulator [SERM] or aromatase inhibitors) within 6 months of study entry
  -  Underlying medical, psychiatric or social conditions that would preclude patient from receiving treatment

Relevance to patient case: not relevant